Ciproxin licensed for UTI in children

The licence for Ciproxin (ciprofloxacin) has been extended to include the second- and third-line treatment of complicated UTIs and pyelonephritis in children and adolescents aged between 1-17 years.

The dose is 10-20mg/kg orally every 12 hours up to a maximum of 750mg per dose. The recommended duration of treatment is 10-21 days.

View Ciproxin drug record

Further information: Bayer plc

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New rapidly acting insulin launched

New rapidly acting insulin launched

Lyumjev is a new 'ultra rapidly acting' formulation...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Statin prescribing 'commonly breaching NICE guidance'

Statin prescribing 'commonly breaching NICE guidance'

Prescribing of suboptimal statin regimens is 'extremely...